TTC29 Variant 2: A Promising Drug Target and Biomarker (G83894)

Target Name: TTC29

NCBI ID: G83894

TTC29

TTC29 Variant 2: A Promising Drug Target and Biomarker

Abstract:

TTC29 variant 2, also known as TTC29-2, is a novel variant of the T-cell Transition Control protein (TTC29) that has been identified through computational analysis. This variant is unique due to a specific amino acid substitution at position 292, which results in a alteration in the protein's stability and function. Despite its small size, TTC29 variant 2 has the potential to be a valuable drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Introduction:

T cells are a crucial immune cell that play a vital role in fighting against infections, cancer, and other diseases. During their maturation and renewal, T cells undergo a series of changes that allow them to adapt to their respective environments. The T-cell Transition Control protein (TTC29) is a key regulator of these changes. It is a transmembrane protein that plays a critical role in regulating the movement and activity of T cells during their transition from an immature to a mature cell.

TTC29 variants have been identified in individuals with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These variants can alter the stability and function of TTC29, leading to disruptions in T cell development and function. The identification of TTC29 variants with specific amino acid substitutions has the potential to provide new insights into the regulation of T cell development and to identify potential drug targets and biomarkers.

In this article, we will focus on TTC29 variant 2, also known as TTC29-2. We will explore its unique features, the implications of this variant for human health, and the potential for its use as a drug target and biomarker.

Structure and Function:

TTC29 is a 21-kDa transmembrane protein that plays a critical role in regulating the transition of T cells from an immature to a mature cell. The protein is composed of an N-terminus, a catalytic C-terminus, and a C-terminal transmembrane region. The N-terminus of TTC29 contains a nucleotide-binding oligomerization domain (NBD), which is responsible for the protein's stability and functions.

TTC29 variants can alter its stability and function by replacing specific amino acids with different ones. One of the most well-studied TTC29 variants is the missense variant TTC29-1, which results in the substitution of Asp for Asn at position 292. This substitution has been shown to significantly reduce the stability of TTC29 and disrupt its function.

TTC29 variant 2, also known as TTC29-2, is a unique variant that results in the substitution of Asp for Asn at position 292. This substitution has a significant impact on the stability and function of TTC29. The new variant has a molecular weight of 42 kDa and a calculated pI of 1.5.

The impact of TTC29 variant 2 on T cell development:

TTC29 is a key regulator of T cell development, and the function of TTC29 variants can have a significant impact on T cell development and function. The substitution of Asp for Asn at position 292 in TTC29 variant 2 disrupts the stability of the protein, leading to a decrease in its function. This decrease in function can result in altered T cell development, including an increase in the size and diversity of T cell populations.

The implications of TTC29 variant 2 for human health:

TTC29 variant 2 has the potential to have a significant impact on human health. The alteration in

Protein Name: Tetratricopeptide Repeat Domain 29

Functions: Axonemal protein which is implicated in axonemal and/or peri-axonemal structures assembly and regulates flagella assembly and beating and therefore sperm motility

The "TTC29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets